- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Paul L. Nguyen, MD | Authors
Radiation Therapy for Node-Positive Prostate Cancer: It’s Time for a Randomized Trial
February 15, 2015
We are in urgent need of a randomized trial comparing radiation plus ADT vs ADT alone for men with node-positive prostate cancer.
ACR Appropriateness Criteria® Postradical Prostatectomy Irradiation in Prostate Cancer
December 16, 2014
The purpose of this article is to present an updated set of American College of Radiology consensus guidelines formed from an expert panel on the appropriate use of radiation therapy in postprostatectomy prostate cancer.
The Role of Radical Prostatectomy and Lymph Node Dissection in the Treatment of Young Men With High-Grade Node-Positive Prostate Cancer: Less Is More-the Benefits of Surgery Do Not Yet Outweigh Potential Harms
June 15, 2014
Under current conditions for patients with newly diagnosed node-positive prostate cancer, the benefits of surgery, if any, are highly unlikely to outweigh the known harms--less is still more.
PSA Screening: The Case in Favor
October 15, 2013
The facts presented about screening should be tailored to the patient’s exact situation, and the patient’s values should be used to guide the final decision. For younger, healthy men, PSA screening should continue to be strongly considered.
Deciding Which Patients to Treat With Salvage Radiotherapy After Prostatectomy
July 15, 2010
In their article, Raldow et al provide an excellent summary of the issues surrounding the use of salvage radiotherapy for a post-prostatectomy recurrence. For practicing clinicians, the pressing issue is how to appropriately select patients for treatment with salvage radiotherapy.
Possible Selection Bias and Lack of Mortality Endpoints Prevent Conclusions About New Standards of Care
August 01, 2008
In this issue of ONCOLOGY, Bittner et al provide a thoughtful review of the literature to advocate for the viewpoint that interstitial brachytherapy should be standard of care for the treatment of high-risk prostate cancer.